The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay, Regina Graul, Amreen Husain, Mansoor Raza Mirza, Brian Slomovitz*

*Corresponding author for this work

Abstract

Metastatic or recurrent endometrioid adenocarcinoma of the uterine corpus is often incurable with limited treatment options. First-line treatment often includes cytotoxic chemotherapy, which incurs significant toxicities for many patients. Endometrial cancer, specifically endometrioid cancer, is a hormone-sensitive disease and, while single-agent hormonal therapies have demonstrated clinical benefit, resistance to these agents often leads to the use of chemotherapy. There is a lack of approved endocrine treatment options in the metastatic setting for most recurrent endometrial cancers, representing an unmet clinical need. Emerging evidence suggests that hormonal therapy in combination with other targeted treatments, such as cyclin dependent kinase (CDK)4/6 inhibitors, is well tolerated and effective in select patient populations. We discuss the clinical evidence suggesting that the combination of CDK4/6 inhibitors and hormonal therapy has the potential to represent an important addition to the first-line treatment options for patients with low-grade advanced or recurrent endometrial cancer.

Original languageEnglish
Article numberijgc-2023-004739
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume33
Issue number12
Pages (from-to)1943-1949
Number of pages7
ISSN1048-891X
DOIs
Publication statusPublished - 4 Dec 2023

Keywords

  • Carcinoma, Endometrioid/drug therapy
  • Cyclin-Dependent Kinase 4/therapeutic use
  • Endometrial Neoplasms/drug therapy
  • Female
  • Humans
  • Neoplasm Recurrence, Local/drug therapy
  • Protein Kinase Inhibitors

Fingerprint

Dive into the research topics of 'The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma'. Together they form a unique fingerprint.

Cite this